Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UCLM802 in Mesothelin-positive Advanced Solid Tumors
NCT05775666Phase 1Unknown
- Sponsor
- Peking University
- Start
- Mar 2023
- Primary completion
- May 2024
- Modality
- CAR-T Cells
01
Overview
Phase 1, open-label, single-arm trial of UCLM802 in solid tumor, sponsored by Peking University. Primary endpoints: Adverse Events at 2 years, Serious Adverse Events at 2 years and 2 more. Status: unknown.
02
Drugs
UCLM802
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05775666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05775666.